NanoEmulsion-Infused Buccal Films: A Hybrid Drug Delivery Platform For Overcoming Solubility Barriers in BCS Class II Drugs

The oral route remains the most convenient and widely accepted method for drug administration. However, drugs belonging to BCS Class II exhibit poor aqueous solubility and variable absorption, leading to low and inconsistent bioavailability. Conventional oral formulations often fail to achieve therapeutic plasma concentrations due to pre-systemic metabolism and enzymatic degradation in the gastrointestinal tract.

The buccal mucosa, with its rich blood supply and permeability, offers an alternative route that bypasses hepatic first-pass metabolism. When combined with nanoemulsion (NE) technology, which enhances solubilization and diffusion of lipophilic drugs, nanoemulsion-loaded buccal films represent a novel approach for controlled and efficient drug delivery.

2. NANOEMULSIONS: AN OVERVIEW

Nanoemulsions are thermodynamically unstable but kinetically stable systems consisting of oil, water, surfactant, and co-surfactant with droplet sizes typically between 20–200 nm. The small droplet size provides:

• High surface area for drug dissolution,
• Improved solubilization of lipophilic compounds, and
• Enhanced mucosal permeation.

2.1 Components of Nanoemulsions

• Oil phase: solubilizes the lipophilic drug (e.g., Capryol 90, Labrafac).
• Surfactant: reduces interfacial tension (e.g., Tween 80, Cremophor EL).
• Co-surfactant: stabilizes the interface (e.g., Transcutol P, PEG 400).
• Aqueous phase: provides dispersion medium.

2.2 Preparation Methods

Common methods include:

• High-pressure homogenization
• Ultrasonication
• Spontaneous emulsification

These techniques ensure uniform droplet distribution and enhanced stability.

3. BUCCAL FILMS: CHARACTERISTICS AND ADVANTAGES

Buccal films are flexible, thin polymeric matrices that adhere to the mucosa and release the drug either locally or systemically. They are prepared using mucoadhesive polymers such as hydroxypropyl methylcellulose (HPMC), sodium alginate, polyvinyl alcohol (PVA), and carbopol.

3.1 Advantages

• Bypasses hepatic first-pass metabolism
• Rapid onset of action
• Improved patient compliance
• Possibility of controlled or sustained release
• Ease of removal and administration

3.2 Evaluation Parameters

Films are evaluated for:

• Thickness and weight uniformity
• Folding endurance
• Surface pH
• Tensile strength
• Drug content and in-vitro release
• Ex-vivo mucoadhesion and permeation studies

4. INTEGRATION OF NANOEMULSIONS INTO BUCCAL FILMS

Loading nanoemulsions into buccal films combines solubilization power with mucoadhesive retention. The integration process involves:

1. Preparation of optimized nanoemulsion using pseudo-ternary phase diagram.
2. Incorporation into polymeric film-forming solution.
3. Casting and drying to form uniform buccal films.

This hybrid delivery system ensures sustained drug release and improved mucosal permeation due to the nanodroplet size and lipidic composition.

5. MECHANISM OF DRUG ABSORPTION

Upon administration, the film adheres to the mucosal surface and gradually hydrates, releasing the nanoemulsion droplets. The nano-sized droplets enhance drug diffusion through:

• Paracellular and transcellular pathways,
• Interaction with mucosal lipids, and
• Improved solubilization at the absorption site.

This results in higher permeation flux and bioavailability compared to conventional buccal films or oral formulations.

6. APPLICATIONS FOR BCS CLASS II DRUGS